Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth; ...

Revenue growth accelerated, margins expanded, and we continued to demonstrate operating leverage as we progress towards profitability. As a reminder, our focus in 2026 centers on three objectives: ...

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

Q1 2026 earnings call: 42% revenue growth, margin expansion, Nodify Lung adoption and raised 2026 guidance to $108–$114M—read now.

Australia’s Industry, Innovation and Science portfolio contains the building blocks of a coordinated approach to place-based ...

First quarter 2026 total revenues of $58.8 million, including net product sales of $54.9 million and contract revenues from collaborations of $3.9 million Generated ...

The 5 myths of the agentic coding apocalypse ...

The numbers coming out of SunHydrogen paint a picture of stark contradictions. On one hand, the company boasts an equity ratio of 98.22 percent, with zero finan ...

Discover the US Navy's newest destroyer entering sea trials. We explain the history of the USS Patrick Gallagher and its ...

At-home gut health tests use DNA or RNA sequencing from a stool sample. Testing your gut health cannot replace an official diagnosis from a doctor. Your results may provide insights into gut ...

Software testing in regulated sectors requires more than speed. See how to integrate AI while preserving accountability and ...